These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 25958319

  • 1. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.
    McMeekin DS, Sill MW, Walker JL, Moore KN, Waggoner SE, Thaker PH, Rizack T, Hoffman JS, Fracasso PM.
    Gynecol Oncol; 2015 Jul; 138(1):36-40. PubMed ID: 25958319
    [Abstract] [Full Text] [Related]

  • 2. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN, Dao F, Bou Zgheib N, Ferguson SE, Sabbatini PJ, Hensley ML, Bell-McGuinn KM, Konner J, Tew WP, Aghajanian C, Chi DS.
    Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
    [Abstract] [Full Text] [Related]

  • 3. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study.
    McMeekin DS, Walker JL, Hartenbach EM, Bookman MA, Koh WJ, Gynecologic Oncology Group.
    Gynecol Oncol; 2009 Jan; 112(1):134-41. PubMed ID: 18962846
    [Abstract] [Full Text] [Related]

  • 4. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
    Nagao S, Nishikawa T, Hanaoka T, Kurosaki A, Iwasa N, Hasegawa K, Fujiwara K.
    Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
    [Abstract] [Full Text] [Related]

  • 5. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
    Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT.
    J Clin Oncol; 2004 Jun 01; 22(11):2159-66. PubMed ID: 15169803
    [Abstract] [Full Text] [Related]

  • 6. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Gould N, Sill MW, Mannel RS, Thaker PH, Disilvestro P, Waggoner S, Yamada SD, Armstrong DK, Wenzel L, Huang H, Fracasso PM, Walker JL.
    Gynecol Oncol; 2012 Apr 01; 125(1):54-8. PubMed ID: 22155262
    [Abstract] [Full Text] [Related]

  • 7. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
    Duska LR, Berkowitz R, Matulonis U, Muto M, Goodman A, McIntyre JF, Klein A, Atkinson T, Seiden MV, Campos S.
    Gynecol Oncol; 2005 Jan 01; 96(1):198-203. PubMed ID: 15589601
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.
    Fleming GF, Fowler JM, Waggoner SE, Copeland LJ, Greer BE, Horowitz I, Sutton G, Schilder RJ, Fracasso PM, Ball HG, McGuire WP.
    J Clin Oncol; 2001 Feb 15; 19(4):1021-9. PubMed ID: 11181665
    [Abstract] [Full Text] [Related]

  • 10. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
    McMeekin DS, Filiaci VL, Thigpen JT, Gallion HH, Fleming GF, Rodgers WH, Gynecologic Oncology Group study.
    Gynecol Oncol; 2007 Jul 15; 106(1):16-22. PubMed ID: 17574073
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.
    Landrum LM, Hyde J, Mannel RS, McMeekin DS, Moore KN, Walker JL.
    Gynecol Oncol; 2011 Sep 15; 122(3):527-31. PubMed ID: 21664657
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.
    Dizon DS, Sill MW, Gould N, Rubin SC, Yamada SD, Debernardo RL, Mannel RS, Eisenhauer EL, Duska LR, Fracasso PM.
    Gynecol Oncol; 2011 Nov 15; 123(2):182-6. PubMed ID: 21820161
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ, Shah CA, Swensen RE, Tamimi HK, Goff BA.
    Gynecol Oncol; 2010 Mar 15; 116(3):340-4. PubMed ID: 19922987
    [Abstract] [Full Text] [Related]

  • 16. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
    Gallion HH, Brunetto VL, Cibull M, Lentz SS, Reid G, Soper JT, Burger RA, Andersen W, Gynecologic Oncology Group Study.
    J Clin Oncol; 2003 Oct 15; 21(20):3808-13. PubMed ID: 14551299
    [Abstract] [Full Text] [Related]

  • 17. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix.
    Thigpen T, Vance RB, Khansur T.
    Semin Oncol; 1995 Oct 15; 22(5 Suppl 12):67-75. PubMed ID: 7481864
    [Abstract] [Full Text] [Related]

  • 18. Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial.
    Soper JT, Reisinger SA, Ashbury R, Jones E, Clarke-Pearson DL.
    Gynecol Oncol; 2004 Oct 15; 95(1):95-100. PubMed ID: 15385116
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study.
    Spirtos NM, Enserro D, Homesley HD, Gibbons SK, Cella D, Morris RT, DeGeest K, Lee RB, Miller DS.
    Gynecol Oncol; 2019 Jul 15; 154(1):13-21. PubMed ID: 31053405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.